MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat

Neuroscience

Volumn 271, Issue , 2014, Pages 1-8

  Ding, G ^a   Zhang, Z ^a   Chopp, M ^a,b   Li, L ^a   Zhang, L ^a   Li, Q ^a   Wei, M ^a   Jiang, Q ^a  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

AcSDKP; BBB; MRI; Rat; Stroke; TPA

Indexed keywords

GADOLINIUM PENTETATE; SERASPENIDE; TISSUE PLASMINOGEN ACTIVATOR; CONTRAST MEDIUM; FIBRIN; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; OLIGOPEPTIDE;

ADJUVANT THERAPY; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; FIBRIN DEPOSITION; HISTOPATHOLOGY; IMAGING SOFTWARE; IMMUNOHISTOCHEMISTRY; MALE; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PERMEABILITY; PRIORITY JOURNAL; RAT; ACUTE DISEASE; ANIMAL; BRAIN; CAPILLARY PERMEABILITY; DIAGNOSTIC USE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; INFARCTION, MIDDLE CEREBRAL ARTERY; LONGITUDINAL STUDY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; WISTAR RAT;

ACUTE DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBRIN; FIBRINOLYTIC AGENTS; GADOLINIUM DTPA; IMMUNOHISTOCHEMISTRY; INFARCTION, MIDDLE CEREBRAL ARTERY; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; RATS, WISTAR; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84899934945     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.04.025     Document Type: Article

References (27)

1. Caso J.R., Pradillo J.M., Hurtado O., Lorenzo P., Moro M.A., Lizasoain I. Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007, 115:1599-1608.
2. Chernysh I.N., Weisel J.W. Dynamic imaging of fibrin network formation correlated with other measures of polymerization. Blood 2008, 111:4854-4861.
3. Datta P.K., Blake M.C., Moses H.L. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta -induced physical and functional interactions between smads and Sp1. J Biol Chem 2000, 275:40014-40019.
4. Ding G., Jiang Q., Zhang L., Zhang Z.G., Li L., Knight R.A., Ewing J.R., Wang Y., Chopp M. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. J Cereb Blood Flow Metab 2005, 25:87-97.
5. Ding G., Jiang Q., Li L., Zhang L., Gang Zhang Z., Ledbetter K.A., Ewing J.R., Li Q., Chopp M. Detection of BBB disruption and hemorrhage by Gd-DTPA enhanced MRI after embolic stroke in rat. Brain Res 2006, 1114:195-203.
6. Ewing J.R., Brown S.L., Lu M., Panda S., Ding G., Knight R.A., Cao Y., Jiang Q., Nagaraja T.N., Churchman J.L., Fenstermacher J.D. Model selection in magnetic resonance imaging measurements of vascular permeability: gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 2006, 26:310-320.
7. Fieschi C., Argentino C., Lenzi G.L., Sacchetti M.L., Toni D., Bozzao L. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989, 91:311-321.
8. Hacke W., Kaste M., Bluhmki E., Brozman M., Davalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
9. Haelewyn B., Risso J.J., Abraini J.H. Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?. J Cereb Blood Flow Metab 2010, 30:900-903.
10. Hamann G.F., Okada Y., del Zoppo G.J. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab 1996, 16:1373-1378.
11. Haring H.P., Berg E.L., Tsurushita N., Tagaya M., del Zoppo G.J. E-selectin appears in nonischemic tissue during experimental focal cerebral ischemia. Stroke 1996, 27:1386-1391. (discussion 1391-1382).
12. Jackson J.D., Ozerol E., Yan Y., Ewel C., Talmadge J.E. Activity of acetyl-Ser-Asp-Lys-Pro (AcSDKP) on human hematopoietic progenitor cells in short-term and long-term bone marrow cultures. J Hematother Stem Cell Res 2000, 9:489-496.
13. Liu J.M., Lawrence F., Kovacevic M., Bignon J., Papadimitriou E., Lallemand J.Y., Katsoris P., Potier P., Fromes Y., Wdzieczak-Bakala J. The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 2003, 101:3014-3020.
14. Lo E.H., Pan Y., Matsumoto K., Kowall N.W. Blood-brain barrier disruption in experimental focal ischemia: comparison between in vivo MRI and immunocytochemistry. Magn Reson Imaging 1994, 12:403-411.
15. Lo E.H., Wang X., Cuzner M.L. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 2002, 69:1-9.
16. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 1997, 28:2109-2118. NINDS.
17. Rasoul S., Carretero O.A., Peng H., Cavasin M.A., Zhuo J., Sanchez-Mendoza A., Brigstock D.R., Rhaleb N.E. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension. J Hypertens 2004, 22:593-603.
18. Rhaleb N.E., Pokharel S., Sharma U.C., Peng H., Peterson E., Harding P., Yang X.P., Carretero O.A. N-Acetyl-Ser-Asp-Lys-Pro inhibits interleukin-1beta-mediated matrix metalloproteinase activation in cardiac fibroblasts. Pflugers Arch 2013, 465:1487-1495.
19. Rosell A., Lo E.H. Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008, 8:82-89.
20. Walker J.B., Nesheim M.E. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999, 274:5201-5212.
21. Wang D., Carretero O.A., Yang X.Y., Rhaleb N.E., Liu Y.H., Liao T.D., Yang X.P. N-Acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004, 287:H2099-H2105.
22. Yang F., Yang X.P., Liu Y.H., Xu J., Cingolani O., Rhaleb N.E., Carretero O.A. Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 2004, 43:229-236.
23. Zhang R.L., Chopp M., Zhang Z.G., Jiang Q., Ewing J.R. A rat model of focal embolic cerebral ischemia. Brain Res 1997, 766:83-92.
24. Zhang Z.G., Chopp M., Goussev A., Lu D., Morris D., Tsang W., Powers C., Ho K.L. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci 1999, 19:10898-10907.
25. Zhang L., Zhang Z.G., Chopp M. The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci 2012, 33:415-422.
26. Zhang L., Chopp M., Teng H., Ding G., Jiang Q., Yang X.P., Rhaleb N.E., Zhang Z.G. Combination treatment with AcSDKP and tissue plasminogen activator provides potent neuroprotection in rats after stroke 2014, 45:1108-1114.
27. Zhuo J.L., Carretero O.A., Peng H., Li X.C., Regoli D., Neugebauer W., Rhaleb N.E. Characterization and localization of Ac-SDKP receptor binding sites using 125I-labeled Hpp-Aca-SDKP in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2007, 292:H984-H993.